AstraZeneca Drug Approval Expected to Boost SERD Market Growth
The approval of AstraZeneca's ETCAMAH and improved diagnostics are projected to accelerate the growth of the Selective Estrogen Receptor Degrader (SERD) market between 2026 and 2036.
The market for Selective Estrogen Receptor Degraders (SERDs) is poised for significant growth during the forecast period of 2026–2036, with analyst expectations pointing to a considerable expansion. Key factors driving this projection include advancements in diagnosis, improved treatment options, and increased patient awareness.
AstraZeneca's recent approval of ETCAMAH (camizestrant), an oral SERD, is identified as a primary catalyst for this anticipated market growth. The development and successful market entry of such therapies are crucial for addressing unmet needs in specific cancer treatments.
The growth is expected to be particularly pronounced across the seven major markets (7MM). Beyond drug approvals, demographic shifts and supportive regulatory environments are also contributing to the wider adoption of SERD therapies, according to market observers.
SERDs are a class of drugs primarily used in the treatment of hormone receptor-positive breast cancer. The ongoing development and market introduction of new SERD agents are expected to meet the evolving needs of patients and clinicians in oncology.